| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| Other Sizes |
| Targets |
The compound does not have a well-defined pharmacological target in the context of drug development. It is a leucine derivative used as a fluorescent probe. The dansyl group provides fluorescent properties that enable detection and quantification in various assays.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
Dansylleucine is a leucine derivative. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. They influence the secretion of anabolic hormones, supply of fuel during exercise, mental performance during stress related tasks, and prevent exercise induced muscle damage. The compound's dansyl group provides fluorescent properties for detection. |
| ln Vivo |
Dansylleucine is a leucine derivative. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. They influence the secretion of anabolic hormones, supply of fuel during exercise, mental performance during stress related tasks, and prevent exercise induced muscle damage.
|
| Enzyme Assay |
In vitro enzymatic or receptor binding assays for Dansylleucine may involve the use of amino acid transporters. The compound's fluorescent properties enable detection in transport assays. However, specific assay protocols are not well-documented.
|
| Cell Assay |
In vitro cell-based assays for Dansylleucine may involve the use of cells expressing amino acid transporters. The compound's fluorescent properties enable detection of cellular uptake and transport. However, specific cell-based assay protocols are not well-documented.
|
| Animal Protocol |
In vivo animal studies for Dansylleucine are not well-documented. The compound is a leucine derivative used in research applications. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements.
|
| ADME/Pharmacokinetics |
Dansylleucine has a molecular weight of 364.46 and a molecular formula of C18H24N2O4S. It has a CAS number of 1100-22-7. The compound is a leucine derivative with a dansyl group. It has a melting point of 126°C. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Dansylleucine. The compound is for research use only and is not intended for human therapeutic use. It is a leucine derivative and is generally considered safe for research purposes.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Dansylleucine (Dansyl-L-leucine) is a leucine derivative. It has a molecular weight of 364.46 and a molecular formula of C18H24N2O4S. The compound has a CAS number of 1100-22-7. It is a bioactive chemical compound used in research applications. The dansyl group provides fluorescent properties for detection and quantification in various assays. The compound is for research use only and has not been approved for clinical use.
|
| Molecular Formula |
C18H24N2O4S
|
|---|---|
| Molecular Weight |
364.46
|
| Exact Mass |
364.146
|
| CAS # |
1100-22-7
|
| PubChem CID |
150881
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.256g/cm3
|
| Boiling Point |
545ºC at 760mmHg
|
| Melting Point |
126ºC
|
| Flash Point |
283.4ºC
|
| Vapour Pressure |
1.03E-12mmHg at 25°C
|
| Index of Refraction |
-9.5 ° (C=1, EtOH)
|
| LogP |
4.155
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
25
|
| Complexity |
556
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(C1=C([H])C([H])=C([H])C2C(=C([H])C([H])=C([H])C1=2)N(C([H])([H])[H])C([H])([H])[H])(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])(=O)=O
|
| InChi Key |
XBMQRPDOXIPUFG-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C18H24N2O4S/c1-12(2)11-15(18(21)22)19-25(23,24)17-10-6-7-13-14(17)8-5-9-16(13)20(3)4/h5-10,12,15,19H,11H2,1-4H3,(H,21,22)/t15-/m0/s1
|
| Chemical Name |
(2S)-2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-4-methylpentanoic acid
|
| Synonyms |
Dansyl-leucine; Dns-leucine; Dansylleucine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~685.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7438 mL | 13.7189 mL | 27.4379 mL | |
| 5 mM | 0.5488 mL | 2.7438 mL | 5.4876 mL | |
| 10 mM | 0.2744 mL | 1.3719 mL | 2.7438 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
